Agyany Pharma

Company Overview

Snapshot

Founded in April 2026, Agyany Pharma is a biopharmaceutical company with 1–10 employees. Co-Founder and Chief Medical Officer Prof. Dr. Ari Zimran leads the development of disease-modifying treatments for Parkinson's disease, with its lead program currently in clinical trial stage.

Business overview

Agyany Pharma is a clinical-stage biopharmaceutical company focused on developing disease-modifying treatments for Parkinson's disease and related neurodegenerative disorders. The company's core technology involves repurposing Ambroxol to target the underlying molecular mechanisms of GBA1-associated Parkinson's disease, aiming to address the root cause rather than just symptoms. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Drugs Discovery & Development, Agyany Pharma combines clinical expertise, genetics, and neuroscience to advance novel therapies through clinical development, serving the medical industry with the goal of improving outcomes for patients.

Company Intelligence Q&A

When was Agyany Pharma founded?

Agyany Pharma was founded in April 2026.

What is Agyany Pharma's primary focus?

Agyany Pharma focuses on developing disease-modifying therapies for Parkinson's disease and related neurodegenerative disorders.

Who is a key member of Agyany Pharma's leadership team?

Prof. Dr. Ari Zimran serves as the Co-Founder and Chief Medical Officer at Agyany Pharma.

What is the current product stage of Agyany Pharma's lead program?

Agyany Pharma's lead program, which aims to repurpose Ambroxol for GBA1-associated Parkinson's disease, is currently in the clinical trial stage.

What is Agyany Pharma's primary sector?

Agyany Pharma operates primarily within the Health Tech & Life Sciences sector.